journal article·2020-05-12Open access

Formulation Strategies to Improve Oral Bioavailability of Ellagic Acid

Guendalina Zuccari, Sara Baldassari, Giorgia Ailuno, Federica Turrini, Silvana Alfei, Gabriele Caviglioli

Applied Sciences· Volume 10· Issue 10

Abstract

Ellagic acid, a polyphenolic compound present in fruit and berries, has recently been the object of extensive research for its antioxidant activity, which might be useful for the prevention and treatment of cancer, cardiovascular pathologies, and neurodegenerative disorders. Its protective role justifies numerous attempts to include it in functional food preparations and in dietary supplements, and not only to limit the unpleasant collateral effects of chemotherapy. However, ellagic acid use as a chemopreventive agent has been debated because of its poor bioavailability associated with low solubility, limited permeability, first pass effect, and interindividual variability in gut microbial transformations. To overcome these drawbacks, various strategies for oral administration including solid dispersions, micro and nanoparticles, inclusion complexes, self-emulsifying systems, and polymorphs were proposed. Here, we listed an updated description of pursued micro and nanotechnological approaches focusing on the fabrication processes and the features of the obtained products, as well as on the positive results yielded by in vitro and in vivo studies in comparison to the raw material. The micro and nanosized formulations here described might be exploited for pharmaceutical delivery of this active, as well as for the production of nutritional supplements or for the enrichment of novel foods.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Pomegranate: compositions and health benefits · Phytase and its Applications · Ginkgo biloba and Cashew Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy, Università di Genova, 16147 Genova, Italy

References (100+)

Show source-provided references
1. Pomegranate (Punica granatum L.): A medicinal plant with myriad biological properties—A short review
2. A Pharmacological Update of Ellagic Acid10.1055/a-0633-9492 ↗
3. Recent Advances in Anticancer Activities and Drug Delivery Systems of Tannins10.1002/med.21422 ↗
4. The antidiabetic and antioxidant properties of some phenolic phytochemicals: A review study10.1016/j.dsx.2018.11.051 ↗
5. Baradaran Rahimi, V., Ghadiri, M., Ramezani, M., and Askari, V.R. (2020). Anti-inflammatory and anti-cancer activities of pomegranate and its constituent, ellagic acid: Evidence from cellular, animal, and clinical studies. Phytother. Res., in press.10.1002/ptr.6565 ↗
6. Ellagic acid a multi-target bioactive compound for drug discovery in CNS? A narrative review10.1016/j.ejmech.2019.111724 ↗
7. Improvements in Metabolic Health with Consumption of Ellagic Acid and Subsequent Conversion into Urolithins: Evidence and Mechanisms10.3945/an.116.012575 ↗
8. Neuroprotective Effects of Ellagic Acid in a Rat Model of Parkinson’s Disease
9. Radiosensitizing effect of ellagic acid on growth of Hepatocellular carcinoma cells: An in vitro study10.1038/s41598-017-14211-4 ↗
10. Anti-cancer Effects of Polyphenolic Compounds in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer10.4103/pm.pm_535_16 ↗
11. Effects of Ellagic Acid on Angiogenic Factors in Prostate Cancer Cells10.3390/cancers5020726 ↗
12. Pomegranate extract inhibits the proliferation and viability of MMTV-Wnt-1 mouse mammary cancer stem cells in vitro
13. Ellagic Acid Inhibits VEGF/VEGFR2, PI3K/Akt and MAPK Signaling Cascades in the Hamster Cheek Pouch Carcinogenesis Model10.2174/1871520614666140723114217 ↗
14. Ceci, C., Tentori, L., Atzori, M., Lacal, P., Bonanno, E., Scimeca, M., Cicconi, R., Mattei, M., de Martino, M., and Vespasiani, G. (2016). Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. Nutrients, 8.10.3390/nu8110744 ↗
15. Main components of pomegranate, ellagic acid and luteolin, inhibit metastasis of ovarian cancer by down-regulating MMP2 and MMP910.1080/15384047.2017.1394542 ↗
16. Ellagic acid inhibits human glioblastoma growth in vitro and in vivo10.3892/or.2016.5331 ↗
17. Ellagic acid and Sennoside B inhibit osteosarcoma cell migration, invasion and growth by repressing the expression of c-Jun
18. Ceci, C., Lacal, P., Tentori, L., De Martino, M., Miano, R., and Graziani, G. (2018). Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. Nutrients, 10.10.3390/nu10111756 ↗
19. Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells10.1007/s11010-014-2257-2 ↗
20. Ellagic acid ameliorates cisplatin induced hepatotoxicity in colon carcinogenesis10.1002/tox.22747 ↗
21. Preventive Effects of Ellagic Acid Against Doxorubicin-Induced Cardio-Toxicity in Mice10.1007/s12012-013-9197-z ↗
22. Development of Biodegradable Nanoparticles for Oral Delivery of Ellagic Acid and Evaluation of Their Antioxidant Efficacy Against Cyclosporine A-Induced Nephrotoxicity in Rats10.1007/s11095-006-9207-y ↗
23. Ellagic acid biological properties and biotechnological development
24. Concerted inhibitory activities of Phyllanthus amarus on HIV replication in vitro and ex vivo
25. Healing potential of Anogeissus latifolia for dermal wounds in rats
26. Intestinal ellagitannin metabolites ameliorate cytokine-induced inflammation and associated molecular markers in human colon fibroblasts10.1021/jf300290f ↗
27. Anti-inflammatory effect and mechanism of action of ellagic acid-3,3’,4-trimethoxy-4’-O-α-L-rhamnopyranoside isolated from Hopea parviflora in lipopolysaccharide-stimulated RAW 264.7 macrophages
28. Antiatherogenic effects of ellagic acid and urolithins in vitro10.1016/j.abb.2016.02.017 ↗
29. Protective Effects of Ellagic Acid on Cardiovascular Injuries Caused by Hypertension in Rats10.1055/s-0043-103281 ↗
30. From pomegranate marcs to a potential bioactive ingredient: A recycling proposal for pomegranate squeezed-marcs10.1007/s00217-019-03339-4 ↗
31. Anti-wrinkle activity of Platycarya strobilacea extract and its application as a cosmeceutical ingredient
32. Effects of ellagic acid-rich extract of pomegranates peel on regulation of cholesterol metabolism and its molecular mechanism in hamsters10.1039/C4FO00759J ↗
33. Boggia, R., Turrini, F., Villa, C., Lacapra, C., Zunin, P., and Parodi, B. (2016). Green extraction from pomegranate marcs for the production of functional foods and cosmetics. Pharmaceuticals, 9.10.3390/ph9040063 ↗
34. Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients10.1002/mnfr.201300931 ↗
35. Pomegranate supplementation improves cognitive and functional recovery following ischemic stroke: A randomized trial10.1080/1028415X.2018.1436413 ↗
36. Analytical methods for assay of ellagic acid and its solubility studies10.1016/j.jpba.2005.07.006 ↗
37. pH-Dependent radical scavenging capacity of green tea catechins10.1021/jf0712189 ↗
38. Preparation method and stability of ellagic acid-rich pomegranate fruit peel extract10.3109/13880200903078503 ↗
39. Transport of Corilagin, Gallic Acid, and Ellagic Acid from Fructus Phyllanthi Tannin Fraction in Caco-2 Cell Monolayers10.1155/2016/9205379 ↗
40. Absorption metabolism and antioxidant effects of pomegranate
41. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours10.1093/jn/136.10.2481 ↗
42. Ellagic acid metabolism by human gut microbiota: Consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status10.1021/jf5024615 ↗
43. Urolithins, the rescue of “old” metabolites to understand a “new” concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status10.1002/mnfr.201500901 ↗
44. The gut microbiota urolithin metabotypes revisited: The human metabolism of ellagicacid is mainly determined by aging10.1039/C8FO00956B ↗
45. Identifying the limits for ellagic acid bioavailability: A crossover pharmacokinetic study in healthy volunteers after consumption of pomegranate extracts10.1016/j.jff.2015.09.019 ↗
46. Phytonutrient intakes in relation to European fruit and vegetable consumption patterns observed in different food surveys10.1017/S0007114514001950 ↗
47. Intestinal epithelial cell accumulation of the cancer preventive polyphenol ellagic acid—Extensive binding to protein and DNA10.1016/S0006-2952(03)00413-1 ↗
48. Synthesis of PLGA nanoparticles of tea polyphenols and their strong in vivo protective effect against chemically induced DNA damage10.2147/IJN.S226028 ↗
49. PLGA Nanoparticles Improve the Oral Bioavailability of Curcumin in Rats: Characterizations and Mechanisms10.1021/jf202135j ↗
50. Resveratrol-Loaded Nanoparticles Based on Poly (epsilon-caprolactone) and Poly (d l-lactic-co-glycolic acid)–Poly (ethylene glycol) Blend for Prostate Cancer Treatment10.1021/mp400342f ↗
51. The rate of solution of solid substances in their own solutions10.1021/ja02086a003 ↗
52. Preparation and characterization of micronized ellagic acid using antisolvent precipitation for oral delivery10.1016/j.ijpharm.2015.03.071 ↗
53. (2006). Committee for Human Medicinal Products ICH guideline Q3C
54. (R6) on impurities: Guideline for residual solvents. EMA/CHMP/ICH/82260/, 2006, 1-39.
55. Ellagic acid microspheres restrict the growth of Babesia and Theileria in vitro and Babesia microti in vivo10.1186/s13071-019-3520-x ↗
56. Generation of microparticles of ellagic acid by supercritical antisolvent process10.1016/j.supflu.2016.05.019 ↗
57. Storage Stability of Microencapsulated Cloudberry (Rubus chamaemorus) Phenolics10.1021/jf801868h ↗
58. Stability and solubility enhancement of ellagic acid in cellulose ester solid dispersions10.1016/j.carbpol.2012.10.051 ↗
59. Preparation of ellagic acid micro and nano formulations with amazingly increased water solubility by its entrapment in pectin or non-PAMAM dendrimers suitable for clinical applications10.1039/C8NJ05657A ↗
60. (2017, February 02). Food Additive Database. Available online: https://webgate.ec.europa.eu/foods_system/main/?sector=FAD&auth=SANCAS.
61. Nanoformulated ellagic acid ameliorates pentylenetetrazol-induced experimental epileptic seizures by modulating oxidative stress, inflammatory cytokines and apoptosis in the brains of male mice10.1007/s11011-019-00502-4 ↗
62. Characterisation and anti-inflammatory evaluation of the inclusion complex of ellagic acid with hydroxypropyl-β-cyclodextrin10.1007/s10847-015-0498-7 ↗
63. Inclusion complex of ellagic acid with β-cyclodextrin: Characterization and in vitro anti-inflammatory evaluation10.1016/j.molstruc.2015.08.054 ↗
64. Wang, H., Zhang, Y., Tian, Z., Ma, J., Kang, M., Ding, C., and Ming, D. (2017). Preparation of β-CD-Ellagic Acid Microspheres and Their Effects on HepG2 Cell Proliferation. Molecules, 22.10.3390/molecules22122175 ↗
65. Cyclodextrin-based nanosponge for improvement of solubility and oral bioavailability of Ellagic acid
66. Joseph, E., and Singhvi, G. (2019). Nanomaterials for Drug Delivery and Therapy, Elsevier.
67. Lu, G.W., and Gao, P. (2010). Handbook of Non-Invasive Drug Delivery Systems, Elsevier.
68. Preparation and process optimization of pomegranate ellagic acid-hydroxypropyl-β-cyclodextrin inclusion complex and its antibacterial activity in vitro
69. Biopharmaceutical and antifungal properties of ellagic acid-cyclodextrin using an in vitro model of invasive candidiasis10.2217/fmb-2019-0107 ↗
70. Investigation of the biological and anti-cancer properties of ellagic acid-encapsulated nano-sized metalla-cages10.2147/IJN.S88289 ↗
71. Application of Eudragit P-4135F for the delivery of ellagic acid to the rat lower small intestine10.1211/0022357011776469 ↗
72. PLGA-based nanoparticles: An overview of biomedical applications10.1016/j.jconrel.2012.01.043 ↗
73. Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration10.1080/10611860600565987 ↗
74. Nanoencapsulation of pomegranate bioactive compounds for breast cancer chemoprevention10.2147/IJN.S65145 ↗
75. CS-PEG decorated PLGA nano-prototype for delivery of bioactive compounds: A novel approach for induction of apoptosis in HepG2 cell line10.1016/j.advms.2017.01.003 ↗
76. Enhanced anticancer activity and oral bioavailability of ellagic acid through encapsulation in biodegradable polymeric nanoparticles10.2147/IJN.S147740 ↗
77. Ellagic acid encapsulated chitosan nanoparticles for drug delivery system in human oral cancer cell line (KB)10.1016/j.colsurfb.2013.03.039 ↗
78. Ellagic acid encapsulated chitosan nanoparticles as anti-hemorrhagic agent10.1016/j.carbpol.2014.03.093 ↗
79. Preparation of Chitosan/Alginate-ellagic acid sustained-release microspheres and their Inhibition of preadipocyte adipogenic differentiation10.2174/1389201020666190809110511 ↗
80. Novel oral administrated ellagic acid nanoparticles for enhancing oral bioavailability and anti-inflammatory efficacy10.1016/j.jddst.2018.05.021 ↗
81. Polyester dendritic systems for drug delivery applications: In vitro and in vivo evaluation10.1021/bc010102u ↗
82. Alfei, S., Marengo, B., and Domenicotti, C. (2020). Polyester-Based Dendrimer Nanoparticles Combined with Etoposide Have an Improved Cytotoxic andmPro-Oxidant Effect on Human Neuroblastoma Cells. Antioxidants, 9.10.3390/antiox9010050 ↗
83. Tesauro, D., Accardo, A., Diaferia, C., Milano, V., Guillon, J., Ronga, L., and Rossi, F. (2019). Peptide based drug delivery systems in biotechnological applications. Molecules, 24.10.3390/molecules24020351 ↗
84. Fabrication of ellagic acid incorporated self-assembled peptide microtubes and their applications10.1016/j.colsurfb.2012.02.031 ↗
85. Nano graphene oxide: A novel carrier for oral delivery of flavonoids10.1016/j.colsurfb.2014.09.036 ↗
86. Functionalized graphene oxide as nanocarrier for loading and delivery of ellagic acid10.2174/092986711797287548 ↗
87. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages10.4103/1735-5362.235156 ↗
88. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): Recent advances in drug delivery10.1007/s40005-013-0087-y ↗
89. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach10.1016/j.ijpharm.2015.09.014 ↗
90. Enhanced anti-cancer capability of ellagic acid using solid lipid nanoparticles (SLNs)10.5812/ijcm.9402 ↗
91. Enhanced oral bioavailability and antioxidant profile of ellagic acid by phospholipids10.1021/jf8037105 ↗
92. Nanoliposome-encapsulated ellagic acid prevents cyclophosphamide-induced rat liver damage10.1007/s11010-019-03541-8 ↗
93. Enhancing anti-inflammation activity of curcumin through O/W nanoemulsions10.1016/j.foodchem.2007.10.086 ↗
94. Self nanoemulsifying drug delivery system of stabilized ellagic acid–phospholipid complex with improved dissolution and permeability10.1016/j.jsps.2014.11.001 ↗
95. A food-grade self-nanoemulsifying delivery system for enhancing oral bioavailability of ellagic acid10.1016/j.jff.2017.04.033 ↗
96. Self-microemulsifying drug delivery system (SMEDDS)—Challenges and road ahead10.3109/10717544.2014.896058 ↗
97. Preparation of a supersaturatable self-microemulsion as drug delivery system for ellagic acid and evaluation of its antioxidant activities10.1016/j.jddst.2019.101209 ↗
98. Co-encapsulation of antioxidants into niosomal carriers: Gastrointestinal release studies for nutraceutical applications10.1016/j.colsurfb.2013.09.058 ↗
99. The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q10 ameliorates hyperlipidemia in high fat diet fed rats10.1166/jnn.2009.1461 ↗
100. Development of NIPAAm-PEG acrylate polymeric nanoparticles for co-delivery of paclitaxel with ellagic acid for the treatment of breast cancer10.1515/polyeng-2018-0169 ↗